Table 1 Results from the 28 antibodies deemed significant by the data dichotomization approach. The antibody levels that maximized the separation between the susceptible and protected group of individuals (Cut-off) and the proportion of seropositive individuals for all (Total), Protected (Prt) and susceptible (Sus) children, respectively
Antibody | P-value | Cutoff (95% CI) | Total | Prt | Sus |
|---|---|---|---|---|---|
msp1 | 0.01 | 0.14 (0.04;0.99) | 0.85 | 0.91 | 0.73 |
msp2 | < 0.01 | 0.07 (0.04;0.34) | 0.45 | 0.57 | 0.20 |
msp4 | < 0.01 | 0.13 (0.10;1.36) | 0.86 | 0.96 | 0.65 |
msp5 | 0.02 | 0.09 (0.06;0.23) | 0.56 | 0.64 | 0.40 |
msp10 | < 0.01 | 0.25 (0.11;1.57) | 0.79 | 0.90 | 0.58 |
pf12 | < 0.01 | 0.10 (0.07;0.45) | 0.65 | 0.75 | 0.45 |
pf92 | < 0.01 | 0.11 (0.05;1.32) | 0.83 | 0.91 | 0.65 |
pf34 | < 0.01 | 0.07 (0.05;0.15) | 0.61 | 0.72 | 0.40 |
pf113 | 0.02 | 0.05 (0.04;0.13) | 0.74 | 0.81 | 0.60 |
gama | < 0.01 | 0.05 (0.04;0.11) | 0.61 | 0.72 | 0.40 |
ama1 | < 0.01 | 0.16 (0.04;1.09) | 0.74 | 0.84 | 0.53 |
eba175 | < 0.01 | 0.14 (0.10;1.81) | 0.71 | 0.84 | 0.45 |
eba140 | < 0.01 | 0.11 (0.11;1.55) | 0.96 | 1.00 | 0.88 |
eba181 | < 0.01 | 0.11 (0.09;1.46) | 0.90 | 0.96 | 0.78 |
mtrap | 0.01 | 0.05 (0.04;0.12) | 0.85 | 0.91 | 0.73 |
asp | < 0.01 | 0.08 (0.07;0.15) | 0.70 | 0.79 | 0.53 |
msp3 | 0.01 | 0.08 (0.04;0.30) | 0.48 | 0.57 | 0.30 |
msp6 | < 0.01 | 0.12 (0.10;0.32) | 0.78 | 0.86 | 0.60 |
msp7 | < 0.01 | 0.24 (0.10;1.27) | 0.71 | 0.86 | 0.40 |
msrp1 | < 0.01 | 0.05 (0.05;0.22) | 0.79 | 0.88 | 0.63 |
msrp3 | < 0.01 | 0.04 (0.04;0.10) | 0.96 | 1.00 | 0.88 |
h101 | 0.03 | 0.05 (0.04;0.11) | 0.74 | 0.80 | 0.60 |
h103 | < 0.01 | 0.07 (0.04;0.24) | 0.50 | 0.60 | 0.28 |
pf41 | < 0.01 | 0.12 (0.04;0.53) | 0.38 | 0.48 | 0.18 |
pff0335c | < 0.01 | 0.05 (0.04;0.35) | 0.88 | 0.95 | 0.75 |
rh5 | 0.04 | 0.16 (0.09;0.25) | 0.39 | 0.46 | 0.25 |
ron6 | 0.02 | 0.04 (0.04;0.11) | 0.81 | 0.88 | 0.68 |
pf11_0373 | < 0.01 | 0.08 (0.05;0.14) | 0.21 | 0.28 | 0.05 |